Please login to the form below

Not currently logged in
Email:
Password:

Hikma appoints group scientific officer and global head of R&D

Dr Surendera Tyagi joins the pharma group from Fresenius Kabi

Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr Surendera Tyagi, who will focus on the group’s non-injectables business and will become a member of Hikma’s executive committee.

He joins the pharma group from Fresenius Kabi, where he most recently led its US innovation and development centre.

Prior to this, he served as chief scientific officer for Sabur Pharma, an oncology company that was acquired by Fresenius in 2008.

Tyagi has also held various scientific and regulatory roles at Roche IGEN, Abbott/Hospita and Scwarz Pharma.

He said: “Hikma’s track record of delivering affordable, quality medicines to people who need them is a purpose that I share, and I look forward to accelerating their R&D efforts by advancing and expanding their pipeline.”

22nd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics